Ameet Nathwani

MD, MRCP, DipPharmMed, MBA


Dr. Nathwani is Chief Executive Officer and member of the Board of Directors at Dewpoint, the first company to apply the emerging understanding of biomolecular condensates to drug discovery.  With more than 25 years of experience in the pharmaceutical industry, Ameet was most recently an Executive Committee member at Sanofi SA, where he served as Chief Medical Officer, Head of Medical, and Chief Digital Officer and was responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes. Prior to joining Sanofi, Ameet was the Global Head of Medical Affairs and a member of the Pharma Executive Committee at Novartis Pharma AG, where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capabilities. Over his 11 years at Novartis, Ameet held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise, Senior Vice President, and Global Development Head of the Cardiovascular and Metabolic Franchise. Prior to joining Novartis, Ameet held senior roles in R&D at GlaxoSmithKline, SmithKline Beecham, and Glaxo Group Research in both the UK and US. Across his career in R&D, Ameet has been responsible for the development of over twenty drugs, four of which went on to become blockbusters. 

Dr. Nathwani graduated in medicine in London, specialized in cardiology and intensive care medicine, and holds an MBA. 


Calum MacRae

MD, PhD, BSc


Dr. MacRae is Vice-Chair for Scientific Innovation in the Department of Medicine at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, a leading investigator at the BWH Genomics Center, and an expert member of BWH’s Cardiovascular Genetics Program, which evaluates, diagnoses and manages care for inherited cardiac disorder patients. . Dr. MacRae is a cardiologist and geneticist whose clinical interests include investigating new phenotypes and how research findings can be systematically implemented into clinical care. He holds five patents, has authored over 160 peer-reviewed publications and received research funding from the National Institutes of Health’s National Human Genome Research Institute.

Dr. MacRae received his MD from the University of Edinburgh College of Medicine. He completed two internal medicine residency programs: one at Wellcome Trust Centre for Neuroimaging in London and the other at BWH. He completed a fellowship in cardiovascular disease at Massachusetts General Hospital and is board certified in internal medicine and cardiovascular disease.


Michael Klag



Dr. Klag is the former Dean of the Johns Hopkins Bloomberg School of Public Health and is chair of the Association of Schools of Public Health and chair of the NIH Advisory Board on Clinical Research. 

He is a world-renowned kidney disease epidemiologist whose scientific contributions have been in the prevention and epidemiology of kidney disease, hypertension and cardiovascular disease. Dr. Klag directs one of the longest-running longitudinal studies in existence, the Precursors Study, which began in 1946. Previously, he was Director of the Division of General Internal Medicine and was the first Vice Dean for Clinical Investigation at the Johns Hopkins School of Medicine. Dr. Klag is the author of more than 200 publications and was the Editor-in-Chief of the Johns Hopkins Family Health Book.

Dr. Klag earned his MD at the University of Pennsylvania and his MPH from the Johns Hopkins School of Hygiene and Public Health.


David Tovey



Dr. Tovey is Co-Editor in Chief for the Journal of Clinical Epidemiology. He was Editor-in-Chief of The Cochrane Library for over 10 years, responsible for ensuring the quality and relevance of Cochrane Reviews and also for providing support for initiatives aimed at increasing their impact on clinical practice and health policy. He worked previously as Editorial Director for the BMJ Evidence Centre, which is the division of the BMJ Group that produces evidence-based resources for health professionals and the public. Dr. Tovey worked as a General Practitioner in urban practice in South London for 15 years until 2003. 

Dr. Tovey is a Fellow of the UK Royal College of General Practitioners.


Frank Rockhold

PhD, ScM, BA


Dr. Rockhold is a Professor of Biostatistics and Bioinformatics at Duke University Medical Center, Affiliate Professor of Biostatistics at Virginia Commonwealth University, and Managing Partner of HunterRockhold, Inc. His 40+-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he retired as Chief Safety Officer and Senior Vice President of Global Clinical Safety and Pharmacovigilance. He has held faculty appointments at six universities. Dr. Rockhold served for nine years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a past member of the PCORI Clinical Trials Advisory Panel and is currently on the boards of the Frontier Science and Technology Research Foundation, Datavant, and an advisor to EMA. Dr. Rockhold has been a leader in the scientific community in promoting data disclosure and transparency in clinical research and is widely published in major scientific journals across a wide variety of research topics.

Dr. Rockhold holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from The Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. He is an Elected Fellow of both the American Statistical Association and the Society for Clinical Trials, an Accredited Professional Statistician, PStat®, and a Chartered Statistician, CStat.